Cumberland Pharmaceuticals Inc. (CPIX) to Issue Dividend of $1.50 on July 31st

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) announced a dividend on Monday, July 13th. Stockholders of record on Thursday, July 23rd will be paid a dividend of 1.50 per share by the specialty pharmaceutical company on Friday, July 31st. The ex-dividend date is Monday, August 3rd.

Cumberland Pharmaceuticals Stock Down 0.7%

NASDAQ CPIX traded down $0.05 during mid-day trading on Friday, hitting $6.68. The company’s stock had a trading volume of 110,022 shares, compared to its average volume of 117,149. Cumberland Pharmaceuticals has a twelve month low of $1.85 and a twelve month high of $8.09. The company has a current ratio of 0.95, a quick ratio of 0.79 and a debt-to-equity ratio of 0.25. The company’s 50 day simple moving average is $6.29 and its 200 day simple moving average is $4.72. The firm has a market capitalization of $100.09 million, a price-to-earnings ratio of -13.63 and a beta of 0.09.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last released its earnings results on Tuesday, May 5th. The specialty pharmaceutical company reported ($0.13) EPS for the quarter, hitting analysts’ consensus estimates of ($0.13). The company had revenue of $9.13 million for the quarter, compared to analysts’ expectations of $8.50 million. Cumberland Pharmaceuticals had a negative return on equity of 12.01% and a negative net margin of 17.60%.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland’s strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.

The company’s flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.